Emanuele Angelucci
ItalyEmanuele Angelucci
Emanuele Angelucci
Degree in Medicine: Bologna School of Medicine in 1984
General Hematology, Clinical Oncology and Internal Medicine Fellowship (Ancona University School of Medicine).
Director Hematology and Cellular Therapies and the Stem Cell Transplant Program and Cellular Therapies “Alberto Marmont” IRCCS San Martino Polyclinic Hospital in Genoa. 2016 – today
Over 400 scientific papers in indexed journals (Hindex 66 – Scopus May 2024) particularly in the field of treatment of hematologic malignancies and in hematopoietic cell transplantation and problems related to iron overload and toxicity (N Engl J Med 2000, Blood 2002, Ann Intern Med 2020).
In the field of transplantation in hemoglobinopathies he is co-author of the main studies published since the preliminary experiences (N Engl J Med 1987, 1990, 1993 and 2000, Lancet 1985, 1992 and 1993, Ann Inter Med 2002, Blood 1997, 1997, 2002) as well as main author of the European guidelines for transplantation in hemoglobinopathies: Haematologica 2014.
Chair of the Hemoglobinopathies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Francis Ayuk
GermanyFrancis Ayuk
I am a hemato-oncologist and clinical investigator with special interest in stem cell transplantation and cellular therapies. I am currently deputy director of the Department of Stem Cell Transplantation at the UKE in Hamburg, where I also lead the CAR-T cell therapy program.
Peter Bader
GermanyPeter Bader
Peter Bader, MD is Professor of Paediatrics at the Johann Wolfgang Goethe University in Frankfurt a. M., Germany. He received his medical degree from the Eberhard-Karls-University in Tübingen. Since October 2004 he is Head of the Division for Stem Cell Transplantation and Immunology and Vice Director of the University Children’s Hospital in Frankfurt a. M., Germany.
From 2014 to 2018 Prof. Bader was chairman of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). In March 2019 he was Co-President of the 45th Annual EBMT Meeting in Frankfurt.
His research is focused in particular on pre emptive strategies to prevent relapse after allogeneic stem cell transplantation in children and adolescence with malignant diseases as well as the development and application of innovative cell therapies.
André Baruchel
FranceAndré Baruchel
Ali Bazarbachi
LebanonAli Bazarbachi
Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, and Founding Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris in France. Dr. Ali Bazarbachi’s basic and translational research focuses on targeted therapies for hematological malignancies as well as post-transplant pharmacological interventions. He has co-authored more than 380 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Nature Communication, and Cancer Research. He is a cofounder of the International Academy for Clinical Hematology, the Chairman of the EMBMT Leukemia Working Party, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, past President of the Lebanese Society of Hematology, past President of the International Association for Comparative Research on Leukemia and Related Disorders, and Associate Editor of “Bone Marrow Transplantation” and of “Clinical Hematology International”. He garnered multiple prestigious national and international awards including the 2008 award of the French National Academy of Medicine, the 2022 King Hussein Lifetime Achievement Award for Cancer Research, and the Lebanese National Medal of Merit.
Francesca Bonifazi
ItalyFrancesca Bonifazi
Francesca Bonifazi is the Director of the Adult Transplant Program in Bologna, and the head of Advanced Cellular Therapies Unit in Bologna, Italy. She has been the President of the Italian Society of HSCT (GITMO) (2015-19). The major scientific fields of interest are GVHD prophylaxis, transplantation from alternative donors, transplantation in the elderly, transplantation in acute leukemia, early complications.
Lars Bullinger
GermanyLars Bullinger
Lars Bullinger is the Head of the Department of Hematology, Oncology and Cancer Immunology as well as the Charité Stem Cell Facility at the Virchow Campus of the Charité Universitätsmedizin Berlin. Furthermore, he is coordinating the Charité Leukemia, Stem Cell Transplant, and Advanced Cellular Therapy Programs. In addition, he is engaged in translational research with a focus on the integrative analyses of “omics” and “next generation sequencing” data to further refine molecular tumor classification of hematological malignancies and to implement insights into innovative precision medicine approaches.
Andreas Burchert
GermanyAndreas Burchert
Andreas Burchert is the Director of the Department of Hematology, Oncology and Immunology in Marburg, Germany.
He received his medical training at the Charité, Humboldt University Berlin, the University of Bern, and the University of North Carolina. His basic science and translational research focus is molecular pathogenesis of leukemia and the development of targeted and immune-stimulatory interventions in acute and chronic myeloid leukemia.
Corey Cutler
USACorey Cutler
Dr. Corey Cutler is the Medical Director of the Stem Cell Transplantation Program at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. Dr. Cutler is the President-Elect of the American Society for Blood and Marrow Transplantation. His research has focused on the development of novel methods for the prevention and treatment of acute and chronic GVHD.
Rafael de la Cámara
SpainRafael de la Cámara
I am a haematologist involved in haemopoietic transplant activities for the last 35 years. My main areas of interest and research are the infectious complications of SCT patients, particularly CMV infections. From May 2020 to April 2024, I had the honour of being the chair of the Infectious Diseases Working Party of EBMT. I work at the Hospital de la Princesa in Madrid , in the Hematology Department, one of the first units of HCT in Spain.
Marcos de Lima
USAMarcos de Lima
Dr de Lima is Professor of Medicine at the Ohio State University in Columbus, Ohio. He serves as Director of the Blood and Marrow Transplant and Cellular Therapy Program.
His research involves development of new cellular therapies to treat hematologic malignancies and in the prevention of post allogeneic transplant relapse.
Fernando Barroso Duarte
BrazilFernando Barroso Duarte
Dr. Fernando Barroso Duarte, Medical Specialist in Hematology and Hemotherapy (ABHH), PhD in Surgery from the Federal University of Ceará, and postdoctoral fellow at the Fred Hutchinson Cancer Research Center (Fred Hutch)/Seattle Cancer Care Alliance (USA).
He is an Adjunct Professor in the Department of Surgery at UFC, a physician at the University Hospital Walter Cantídio/EBSERH/UFC, and Chief of the Hematology, Clinical Oncology, and Bone Marrow Transplant Service.
He is currently the President of the Brazilian Society of Bone Marrow Transplantation (SBTMO) and coordinator of the Latin American Bone Marrow Transplant Registry in Myelodysplasia since 2016. Additionally, he is the Editor-in-Chief of the Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT).
Carlo Dufour
ItalyCarlo Dufour
Carlo Dufour chairs the Hematology-Oncology Department and the Hematology Unit in G. Gaslini Research Children’s Hospital, Genova, Italy. He founded the Marrow Failure Syndromes Study Group within the Italian Pediatric Hemato-Oncology Association (AIEOP). Acted as Chairman of the Working Party of the Severe Aplastic Anemia (WPSAA) and as Board member of the European Society for Blood and Marrow Transplantation (EBMT) and as member of the Scientific Committee on Marrow Failures of the American Society of Hematology. He currently serves as the chairman of the Scientific Working Group on Granulocyte and Constitutional Marrow Failure Disorders of the European Hematology Association (EHA) and as a member of the Guidelines Commettee of European Hematology Association (EHA).
In august 2020 has been awarded by the EBMT along with Prof Regis Peffault de Latour and prof Antonio Risitano, with the Van Bekkum award as Co PI of the prospective randomized trial RACE (Comparison of classical IST ± Eltombopag) in Severe Aplastic Anemia.
Britta Eiz-Vesper
GermanyBritta Eiz-Vesper
Britta Eiz-Vesper studied biology at the Ernst Moritz Arndt University in Greifswald and completed her doctorate on human pathogenic adenoviruses at the Institute of Virology at Hanover Medical School.
Immediately after her doctorate, Ms. Eiz-Vesper worked in the research and development department of the DRK NSTOB Springe on stem cell biology and genetic engineering issues. Her work was supported by the Dr. Wilhelm Kempe Foundation with a research fellowship at Chicago Children’s Hospital with Dr. Moldwin. Ms. Eiz-Vesper has been working at the Institute of Transfusion Medicine at Hannover Medical School in the field of allogeneic cell therapy since 1999 and was appointed W2 professor in 2009.
Together with her research group and Britta Maecker-Kolhoff she founded the world’s first allogeneic T cell donor registry alloCELL (www.allocell.org) in 2013 to identify suitable T cell donors, provide personalized antiviral T cell immunotherapies for patients in need and programs for monitoring pathogen-specific T cells in immunocompromised patients with and without transplants. To date, more than 620 mono- or multivirus-specific T cell products have been produced and transfused into patients.
Nico Gagelmann
GermanyNico Gagelmann
- Resident physician University Medical Center Hamburg-Eppendorf under supervision of Prof. Nicolaus Kröger in the Department of Stem Cell Transplantation
- Medical school in Hamburg from 2014-2020
- Co-Chair EBMT Trainee Committee
- Chair EBMT-CMWP subcommittee on CAR-T for plasma cell disorders
- Published work on: myelofibrosis, myeloma, MDS, conditioning, relapse prevention
Sebastian Giebel
PolandSebastian Giebel
Prof. Sebastian Giebel is an internal medicine, hematology and clinical transplantation specialist. He is head of the Department of Bone Marrow Transplantation and Onco-Hematology and Deputy Director for Clinical Matters in Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, Poland. Prof. Giebel is the President of the Polish Adult Leukemia Group (PALG) and vice-president of the Polish Lymphoma Research Group (PLRG), leader of the ALL subcommittee of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), member of the European Working Group for Adult Acute Lymphoblastic Leukemia. An author of over 250 scientific papers, including European Leukemia Net recommendations for the management of ALL. In 2017 he was awarded Jedrzej Sniadecki Medal of the Polish Academy of Sciences, the highest national distinction in the field of medicine.
Nicola Gökbuget
GermanyNicola Gökbuget
Nicola Gökbuget is member of the Department for Internal Medicine II, Hematology/Oncology of the University Hospital in Frankfurt. She is head of the Study Center of the department, head of the Study Center of the University Cancer Center (UCT), one of the Scientific Task Force Directors at the UCT and Principal Investigator of the Frankfurt Cancer Institute.
Since more than 20 years she serves as Coordinator of the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) with more than 140 participating hospitals all over Germany. She is coordinating or principal investigator of numerous academic or industry sponsored trials in adult ALL and related diseases such as lymphoblastic lymphoma or Burkitt’s lymphoma. She has founded and established a national registry for acute lymphoblastic leukemia with an associated biobank. The GMALL study center is a national reference center for adult ALL which provides comprehensive services including advice in challenging situations of clinical management.
Nicola Gökbuget is founding and board member of the German Network for Acute and Chronic Leukemias and the European Leukemia Network (ELN). In the ELN she is founding member of the European Working Group for Adult ALL, past chair of the EHA Scientific Working Group for ALL and is editor of the European ALL guideline book.
Raffaella Greco
ItalyRaffaella Greco
Senior Physician in the Hematology and Blood/Marrow Transplant (BMT) Unit of the IRCCS San Raffaele Hospital in Milano, Italy. Hematologist involved in hematopoietic stem cell transplantation (HSCT) and cellular therapies in all spectrum of haematological cancers and non-malignant indications, including autoimmune diseases.
Her expertise in this field encompasses allogeneic and autologous stem cell transplantation (malignant and non-malignant diseases), cellular therapies (i.e. CART cells, Treg-based cell therapies), immune reconstitution, biomarkers, transplant complications (i.e graft versus host disease, infections). Her career has been focused on several clinical research projects on HSCT and cellular therapies. She has (co-)authored many research articles in peer reviewed journal as well as reviews, book chapters and best-practice guidelines in the field.
She has been significantly involved with the European Group for Blood and Marrow Transplantation (EBMT), as Autoimmune Diseases Working Party (ADWP) Chair (2020-24), EBMT Scientific Council Representative with the Education Portfolio (2022-24), co-chair of the EBMT Harmonization Committee (2022-24), EBMT secretary (2024-ongoing), active member of the ADWP and Cellular Therapy & Immunobiology Working Party (CTIWP).
Hildegard Greinix
AustriaHildegard Greinix
Prof. Hildegard T. Greinix
Medical University of Graz, Austria
I have a long-standing research interest in allogeneic hematopoietic cell transplantation (HCT) including transplant immunology with acute and chronic graft-versus-host disease (GVHD) and induction of transplant tolerance. I am a participant in the NIH Consensus Development Project on chronic GVHD focusing on innovative treatments. My translational research projects have been focused on immune-based soluble and cellular biomarkers predictive and diagnostic for chronic GVHD. Another main preclinical and clinical research interest consists of the exploitation of immunotherapeutic strategies in hematologic malignancies including post-transplant cellular therapies. I am the Head of the Division of Hematology of the Medical University of Graz, Austria and I am the chair of the Austrian Stem Cell Transplant Group.
Carmelo Gurnari
ItalyCarmelo Gurnari
After graduating from Pavia medical school (2015) with a thesis in Pediatric Hematology/Oncology, Dr. Gurnari completed his training in Hematology at the University of Rome, Tor Vergata and then decided to continue his education with a Ph.D program in “Immunology, Molecular Medicine and Applied Biotechnology”. Simultaneously, Dr. Gurnari has been working since 2019 at the Department of Translational Hematology and Oncology Research of Cleveland Clinic (USA) focusing on the genomics of bone marrow failure disorders and myeloid neoplasia. His clinical and translational research expertise encompasses myeloid malignancies with a special focus on germline predisposition and MDS. Dr. Gurnari is a member of the EHA, ASH, and of the EBMT, for which he serves as vice-chair of the CMWP MDS subcommittee. In these years, Dr. Gurnari has been awarded several international prizes such as the Tito Bastianello Young Investigator Award in MDS research and the ASH-IPIG Award for PNH research.
Krzysztof Kalwak
PolandKrzysztof Kalwak
Prof. dr hab. Krzysztof Kalwak (born 1969 in Wroclaw, Poland)
Chair of the EBMT Pediatric Diseases Working Party (since April 2023)
Head of Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland (since Oct 2021)
He graduated from Wroclaw Medical Academy in 1995 and attended research scholarships at the Universities of Tübingen and Ulm (Germany). During many years of work in the Department of Pediatric Hematology, Oncology and BMT in Wroclaw, he completed subsequent steps of his scientific career and became a full professor in 2014. He is a specialist in pediatrics, clinical immunology, pediatric oncology and hematology, and clinical transplantology.
Prof. Kalwak introduced CAR-T cell therapy for pediatric patients in Poland in 2020. He has been chairing one of the largest pediatric transplant units in Europe. In the last 4 years he was ranked in the Top 50 on the “List of top 100 most influential representatives of Polish medicine”.
Guenther Koehne
USAGuenther Koehne
Guenther Koehne, M.D., Ph.D.
Deputy Director and Chief of Blood & Marrow Transplantation and Hematologic Oncology
Miami Cancer Institute, FLA renowned expert in the application of both autologous and allogeneic stem cell transplantation for the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, Guenther Koehne, M.D., Ph.D., serves as deputy director and chief of Blood & Marrow Transplantation, Hematologic Oncology at Miami Cancer Institute.
Prior to joining the Institute in 2017, he was a leading physician in adult bone marrow transplantation service at Memorial Sloan Kettering Cancer Center in New York and an associate professor of medicine at Weill Cornell Medical College. Dr. Koehne is recognized for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes following allogeneic transplants. He is also known for the development of adoptive immunotherapies for viral complications following allogeneic stem cell transplants.
Nicolaus Kröger
GermanyNicolaus Kröger
Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine.
He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematologica, Bone Marrow Transplantation and Biology ofBlood and Marrow Transplantation. He is also member of numerous Scientific Committees such as ASH, EHA, and ESH.
He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade.
Prof. Kröger has published extensively in his area of expertise and has contributed to more than 650 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia.
Stephanie Lee
USAStephanie Lee
Dr. Stephanie Lee is a Professor at the Fred Hutchinson Cancer Center and the University of Washington. She holds the David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research. She is the Principal Investigator of the Chronic GVHD Consortium, a group of institutions that collaborate to conduct observational and therapeutic trials of chronic GVHD.
Suzanne Lentzsch
USASuzanne Lentzsch
Suzanne Lentzsch, MD, PhD Professor of Medicine Director, Multiple Myeloma and Amyloidosis Service Columbia University New York, New York
Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at the Columbia University Irving Medical Center, New York. Her translational research identifies novel targets for treating MM, MM bone disease, and AL amyloidosis. Dr. Lentzsch is the Co-Chair of the NCI Myeloma Steering Committee, a member of the ASH Scientific Committee for Plasma Cell Neoplasia, the Educational and Steering Committee for the Society of Hematology and Oncology (SOHO), and the SWOG Myeloma Working Group. She co-chairs the Career Development Committee of the International Myeloma Society (IMS). She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.
Franco Locatelli
ItalyFranco Locatelli
Franco Locatelli is a Full Professor of Pediatrics at the Catholic University of the Sacred Heart in Rome and Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy, at the Bambino Gesù Children’s Hospital in Rome. He has been the President of the Italian Association for Pediatric Haematology-Oncology AIEOP from 2004 to 2006, and served as chairman of the European EWOG-MDS consortium from 2005 to 2011. Professor Locatelli is an expert of hematological malignant and non-malignant disorders of childhood. Prof. Locatelli is the author or co-author of 1.349 peer-reviewed articles published in international journals (including New England Journal of Medicine, JAMA, Nature, Nature Genetics, Nature Communications, The Lancet, etc.) with more than 62.570 citations and he has an H-index of 120 (Scopus source). Since February 2019 until now, Prof. Locatelli is serving as President of the National Council of Health (Consiglio Superiore di Sanità). On December 2021, he was nominated 1st Class/Knight Grand Cross (Cavaliere di Gran Croce) by the President of the Italian Republic.
Peihua Lu
ChinaPeihua Lu
Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.
- American Board Certified Hematologist & Oncologist, with American and Chinese Medical License
- Member of the Fourth Executive Committee of the Department of Oncology, Capital Medical University
- Chairman of Hematology Specialty Committee of Chinese Non-government Medical Institutions Association (CNMIA)
- Member of Chinese Marrow Donor Program (CMDP) Expert Committee
- Member of Chinese Society of Clinical Oncology (CSCO) Anti-Leukemia Alliance Expert Committee
- Member of the Hematology Translational Medicine Committee of China Anti-Cancer Association (CACA)
- Member of the Seventh Council of Beijing Medical Education Association
Leo Luznik
USALeo Luznik
Markus Mapara
USAMarkus Mapara
Dr. Mapara is a Professor of Medicine at Columbia University Medical Center, the Director of the Blood and Marrow Transplantation (BMT) Program, and a senior investigator at the Columbia Center for Translational Immunology (CCTI). Dr. Mapara graduated from the University of Heidelberg Medical School/Germany and received his post-graduate training in Internal Medicine and Hematology/Oncology at the Universities of Heidelberg and the University Medical Center Charite of the Humboldt University of Berlin in Germany. Dr. Mapara’s research has focused primarily on the following areas: a) Translational research on hematopoietic stem cell transplantation. In particular, he is interested in the immunobiology of allogeneic blood or marrow transplantation to prevent development of GVHD; b) Allogeneic stem cell transplantation and gene therapy for patients with Sickle Cell Disease and Hemoglobinopathies.
Donal McLornan
UKDonal McLornan
Donal McLornan
Dr Donal McLornan graduated in 1999 from Queen’s University Belfast with Honours. Postgraduate training was completed in Belfast with a further one-year period spent in Hammersmith Hospital, London specialising in allogeneic and autologous stem cell transplantation. During his post-graduate training he was awarded a prestigious Medical Research Council fellowship and completed a PhD investigating drug resistance in AML.
Donal works as a consultant in the allogeneic transplant and CAR-T team at University College Hospital London, which has the largest combined transplant and cellular therapy program in the UK. He is the current chair of the Chronic Malignancy Working Party of the EBMT (MPN/MDS/CML/CLL/Plasma cell dyscrasia) and is co-chair of the EBMT scientific council. Additionally, he chairs the UK wide National Cancer Research Institute MPN group. He has a particular interest in MPN, MDS/MPN overlap syndromes and allogeneic stem cell transplantation. His research and clinical trial portfolio focuses on Myelofibrosis and blast phase disease and he has published widely on these topics. He has published >180 peer reviewed papers to date.
Maximilian Merz
GermanyMaximilian Merz
Professor Dr. med. Maximilian Merz
University of Leipzig
Department for Hematology, Cellular Therapy and Hemostaseology
Leipzig, GermanyProf. Merz is Professor of Medicine (Außerplanmäßiger Professor) at the Medical Faculty at University of Leipzig, Leipzig, Germany where is an attending physician and clinician scientist. Since 2022 he is the Head of Early Clinical Trials Unit Leipzig (ECTUL). Last year he received the Translational Research Award by the International Myeloma Society and in 2022 the Helga-Reifert Award from Helga-Reifert-Stiftung for experimental cancer research.
Lori Muffly
USALori Muffly
Lori Muffly is an Associate Professor of Medicine- Blood and Marrow Transplantation and Cellular Therapy- at Stanford University. Her clinical and clinical research focuses on adults with acute leukemia receiving cellular therapies. She holds several National leadership positions and has authored over 100 research publications in the fields of acute leukemia and transplantation.
Fabian Müller
GermanyFabian Müller
Dr. Müller attended the medical school at the Albert-Ludwigs University of Freiburg where he also obtained his Dr. med. with the goal of understanding the epitope binding of B cell receptors better, which he then utilized to target B cells specifically. Dr. Müller started his residency in Hematology and Oncology at the University Hospital of Hamburg Eppendorf, where he continued his work on targeting malignant B cells. The focus of his postdoctoral fellowship with Dr. Ira Pastan, NCI, was to understand resistance to CD22-targeted therapeutics. He continued his work on targeted therapy back at the Friedrich-Alexander University in Erlangen. First with a focus on antibody directed therapies, later he extended his work to CAR T cells. Today he is heading the CAR T cell unit at the University clinic of Erlangen and is leading a Max Eder Research group aiming to develop innovative therapeutic approaches to cancer and autoimmune diseases.
Arnon Nagler
IsraelArnon Nagler
Professor Arnon Nagler, MD, MSc
Chaim Sheba Medical Center, Israel– Director of the Division of Hematology, Chaim Sheba Medical Center, Israel
– Director of Bone Marrow transplantation and Cord Blood Bank, Chaim Sheba Medical Center, Israel
– Professor of Medicine at the Tel Aviv University, Tel Aviv, Israel
– One of the pioneers of the non-myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders (Blood 1998)
– Established the first public cord blood bank and performed the first cord blood transplanataion in Israel
– Leader of the Alternative donor subcommittee of the ALWP of the EBMT from 2008-2010
– Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010
– Serves on the Editorial Board of several BMT and Hematology Journals and is a Section Editor for Leukemia
– Chair of the Acute Leukemia Working Party (ALWP) of the EBMTDr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.
Dr Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many Oral presentations on almost annual basis in all international transplantation and hematology meetings – ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
Alessandro Rambaldi
ItalyAlessandro Rambaldi
Alessandro Rambaldi, MD, is Full Professor of Hematology of the Department of Oncology and Hematology at the University of Milan, Italy. Following his medical degree, he was Associate in Pathology at the Dana Farber Cancer Institute, Boston, USA. Since 2006 he is the Director of the Hematology and Bone Marrow Transplant Unit at the Ospedale Papa Giovanni XXIII, Bergamo, Italy. He is member of the American Society of Hematology (ASH), European Hematology Association (EHA), European Blood and Marrow Transplant group (BMT). From 2010 he served JACIE as Vice Chair and Chair from 2010 to 2015. From 2011 to 2014 he was President of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
His scientific interest ranges from translational research to academic clinical trials in which he pioneered the integration of molecular evaluation of minimal residual disease in the treatment strategy of adult patients with acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. He also led several trials in the field of acute leukemia, lymphomas chronic myeloproliferative neoplasms and allogeneic stem cell transplantation. A current special research interest is the development of innovative cellular therapies for the treatment of leukemia relapse after allogeneic stem cell transplantation.
Prof. Alessandro Rambaldi has published more than 600 manuscripts in peer-reviewed journals such as Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Blood, Leukemia, Haematologica and many others for which he routinely serves as referee.
Antonio Risitano
ItalyAntonio Risitano
Antonio M. Risitano, MD, PhD
AORN San Giuseppe Moscati, Avellino, ItalyAntonio Risitano is Head of the Hematology and BMT Unit at the AORN San Giuseppe Moscati in Avellino, Italy. He graduated in 1997 from the University of Napoli Federico II Medical School in Naples, Italy, where he also completed a residency in haematology under the mentorship of Professor Bruno Rotoli. In 2000, he was awarded a fellowship at the haematology branch of the National Institutes of Health, where he dedicated his time to experimental work on the pathophysiology of bone marrow failure syndromes, under the guidance of Doctor Neal Young. He then moved back to Naples to complete his PhD, serving as a clinical attendant and subsequent research associate in the haematology unit. Professor Risitano was Director of the Bone Marrow Transplantation Program at the University of Napoli Federico II until July 2020, when he moved to his current role.
Professor Risitano has previously focused his activity on clinical management and basic science in the field of aplastic anaemia, paroxysmal nocturnal haemoglobinuria, and idiopathic acquired cytopenias, as well as stem cell transplantation. He has actively contributed to the progress made in this field, with a number of scientific publications describing both clinical trials and biological insights. His current activity includes the management of patients receiving bone marrow transplantations, as well as of those with any bone marrow failures syndrome, including paroxysmal nocturnal haemoglobinuria. He also runs a number of research activities, both clinical and experimental, in the field of paroxysmal nocturnal haemoglobinuria, aplastic anaemia, and bone marrow transplantation, as well in other malignant and non-malignant haematological diseases. Professor Risitano has authored more than 100 publications in the top haematology journals.
Thomas Schroeder
GermanyThomas Schroeder
Prof. Dr. Med. Thomas Michael Schroeder is currently the Managing senior physician, Program Director Allogeneic Stem Cell Transplantation and W3 Professorship for “Translational Allogeneic Stem Cell Transplantation” at the University Hopsital Essen, Germany.
Avichai Shimoni
IsraelAvichai Shimoni
Avichai Shimoni, MD. Medical specialist in internal medicine and Hematology. Completed medical education in Hadassah Medical School in Jerusalem in 1988. Had clinical fellowship in bone marrow transplantation in MD Anderson Cancer Center, Houston, Texas, between the years 1998-2000. Currently, the director of the department of Bone Marrow Transplantation and co-director of the Division of Hematology at the Chaim Sheba Medical Center, Tel-Hashomer. Professor of Hematology in Tel-Aviv University.
Roni Shouval
USARoni Shouval
Dr Roni Shouval is a physician-scientist at Memorial Sloan Kettering Cancer Center in New York. His work is focused on leveraging innovative computational approaches to delineate mechanisms and determinants of toxicity and resistance in patients treated with cellular therapies.
Robert Soiffer
USARobert Soiffer
Robert J. Soiffer, MD, is Chief of the Division of Hematologic Malignancies, Chair of the Executive Committee for Clinical Programs, Vice Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, and Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School.
Dr. Soiffer conducts research focused on modulation of immune responses in the setting of hematopoietic stem cell transplantation. The ultimate goal for his clinical trials and research grants is to optimize graft versus leukemia activity without inducing graft versus host disease.
Dr. Soiffer is a former President of the American Society for Blood and Marrow Transplantation and Past-Chair of the Advisory Board for the Center for International Blood and Marrow Transplant Research. He serves on the Executive Steering Committees for Blood and Marrow Transplant Clinical Trials Network. Dr. Soiffer is a member of the Board of Directors for the National Marrow Donor Program and served as Chair of the Board from 2020 until 2022. Dr. Soiffer serves on the National Cancer Institute’s Leukemia Steering Committee
Dr. Soiffer has co-authored more than 400 peer-reviewed manuscripts and numerous book chapters, review articles, editorials, and monographs. Dr. Soiffer has received several honors and awards including the Casty Family Achievement in Mentoring Award from Dana-Farber, the Brian O’Dell Memorial Research Award from the Leukemia and Lymphoma Society, the George Thorn Award for Outstanding Teaching at Brigham and Women’s Hospital, and the Claire W. and Richard P. morse Research Award.
Matthias Stelljes
GermanyMatthias Stelljes
Prof. Matthias Stelljes earned his medical degree in Kiel. He is currently professor of medicine at the University of Muenster and responsible for the adult allogeneic stem cell transplant program at the University Hospital.
With more than 160 allogeneic transplants for adult patients per year, the transplant program in Muenster is largest transplant centers in Europe.Prof. Stelljes is conducting research in the field of T-cell–mediated immune responses after allogeneic stem cell transplantation. His main clinical focus centers on the optimization of treatment strategies for patients with high-risk/relapsed or refractory hematologic malignancies before and after stem cell transplantation, mainly acute leukemia.
Together with his team, he enrolled substantial numbers of patients in various phase I–III trails, including studies with antiviral drugs, bispecific antibodies / antibody-drug conjugates, novel approaches in conditioning therapies and GvHD treatment. Prof. Stelljes has published numerous peer-reviewed papers in journals including Lancet Oncology, Journal of Clinical Oncology, and Blood, either as a main or co-author.
Jan Styczynski
PolandJan Styczynski
Prof. Jan Styczynski, MD is the Head of the Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. National Consultant in Pediatric hematology and oncology in Poland. Former Chairman and current Secretary of Infectious Diseases Working Party (IDWP) of European Society for Blood and Marrow Transplantation (EBMT). Vice-President of ECIL (European Conference on Infections in Leukemia). Chairman of Infectious Diseases Working Group in Polish Society of Pediatric Hematology and Oncology. Donor of hematopoietic stem cells.
Anna Sureda
SpainAnna Sureda
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català d’Oncologia – Hospitalet, Barcelona. Anna Sureda has focused her career on clinical investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Dr. Sureda was appointed chairperson of the LWP of the EBMT from 2004 to 2010 and secretary of the same organization from 2010 to 2016.
Takanori Teshima
JapanTakanori Teshima
Dr. Teshima is a physician scientist who performs both laboratory and clinical research related to hematopoietic cell transplantation and immune cell therapy. Our laboratory work has provided seminal and deeper understanding of the biology of GVHD. His major laboratory work includes the discovery of the central role of cytokines, target tissue stem cell injury, and intestinal dysbiosis in GVHD. He is taking the initiative of haploidentical HCT and CAR-T therapy in Japan.
